SCIENTIFIC PROGRAM
Thrusday
Friday
Saturday
| WITA | Thrusday, October 10th 2024 | |||
|---|---|---|---|---|
| 07.30-08.00 | REGISTRATION OPENING WORKSHOP | |||
| ROOM | Parallel A (HISBICUS) |
Parallel B
(FRANGIPANI) |
Parallel C
(BOUGAINVILLE) |
Parallel D (For GP)
(ORCHID) |
| 08.00-10.20 |
Workshop 1 Comprehensive Approach of Advanced Dialysis (Focus on HDF) |
Workshop 2 Heading Into a New Era of Anemia Management in CKD |
Workshop 3 A Comprehensive Practical Aspect of Kidney Transplant |
Workshop 4 Update in Hypertension: New Guideline, Target and Trial |
| 08.00-08.10 | Pretest | |||
| 08.10-08.50 | HDF: Solute Transport, Water Treatment and Equipment | The Pathogenesis and Conceptualization of Anemia in CKD | Evaluation of Kidney Transplant Candidate | Current Perspective of Primary Hypertension Management |
| 08.50-09.10 | Clinical Aspect of Hemodiafiltration (HDF) | Anemia Management in CKD: A Step-Wise Approach | Early Management and Monitoring of Post Kidney Transplant Patients | Managing The Hypertensive Patient with Spesific Condition (Pregnancy, Elderly, and CKD) |
| 09.10-09.40 | Effect of HDF on the Removal of Uremic Toxins and Others Clinical Parameters | The Significance of Long-Acting ESA in Management of Anemia Related CKD | Longterm Management in Kidney Transplantation: Foccus in Immunosupresant | Dealing with Hypertensive Emergency and Urgency |
| 09.40-09.50 | Postest | |||
| 09.40-10.20 | Discussion Session | |||
| 10.20-10.50 | COFFEE BREAK | |||
| 10.50-13.10 |
Workshop 5 CAPD as an Options for AKI Management |
Workshop 6 Current and Clinical Approach of Glomerulonephritis |
Workshop 7
Chronic Kidney Disease; Early Detection and Management |
Workshop 8 How to Conduct Systematic Review and Meta-Analysis |
| 10.50-11.00 | Pretest | |||
| 11.00-11.30 | Acute Kidney Injury: Diagnosis and Management | Glomerular Pathology | The Lastest Update and Challenges in CKD | How to Find, Screen and Appraise Best Study |
| 11.30-12.00 | PD as AKI Treatment Option Based on ISPD Guidelines | Diagnosis and Management of Nephrotic Syndrome | The Role of Kidney Profile in Early Detection of CKD | Method and Statistic in Meta- Analysis |
| 12.00-12.30 | Practical Case Sharing of CAPD in AKI | Nephritic Syndrome; Latest Concept and Practical Approach | Urinalysis Application and Case Study in Delaying CKD Progression | How to Report Sys-Rev and Meta-Analysis |
| 12.30-12.40 | Postest | |||
| 12.40-13.10 | Discussion Session | |||
| 13.10 | CLOSING WORKSHOP | |||
| 13.10-14.00 | LUNCH | |||
| 14.00-16.00 | SCIENTIFIC COMPETITION 1 (HISBICUS) |
SCIENTIFIC COMPETITION 2 (FRANGIPANI) |
SCIENTIFIC COMPETITION 3 (BOUGAINVILLE) |
SCIENTIFIC COMPETITION 4 (ORCHID) |
| 16.00 | COFFEE BREAK | |||
| 16.00-18.00 |
RAPAT PENGURUS PB PERNEFRI (NUSANTARA) |
|||
| 18.00-19.00 | BREAK | |||
| 19.00-19.15 |
Dinner Plenary (Invitation Only)
Hemodiafiltration Unveiled: Optimizing Convective and Diffusive Clearance in Renal Replacement Therapy |
|||
| 20.00-22.00 |
RAPAT ANGGOTA PB PERNEFRI (NUSANTARA) |
|||
| WITA | Friday, October 11th 2024 | |
|---|---|---|
| 08.00-09.00 |
OPENING CEREMONY (MANGUPURA) |
|
| 09.00-09.30 |
Plenary 1 (MANGUPURA) ISN/APSN SESSION |
|
| 09.30-10.00 |
Plenary 2 (MANGUPURA) Challenges and Updates in Nephrology Intervention |
|
| 10.00-10.30 | COFFEE BREAK | |
| ROOM | Parallel A (MANGUPURA) | Parallel B (NUSANTARA) |
| 10.30-11.30 |
Symposium 1 (MANGUPURA) Lastest Trend of Dialyzer; Foccus of Current Evidence of Super High-Flux |
Symposium 2 (NUSANTARA)
Extending the Availability of PD Methods and Initiating The procedure in Patients with Sufficient Residual Kidney Function |
| 10.30-10.50 | Introduction of Current Dialyzer Classification | Building and Effective Peritoneal Dialysis Program |
| 10.50-11.10 | Super High-Flux Dialyzer Related to Quality of Life and Mortality | An Innovative Framework for Incremental Peritoneal Dialysis |
| 11.10-11.30 | Discussion Session | |
| 11.30-12.30 |
Symposium 3 (MANGUPURA)
Transforming Kidney Health and The Burden of CKD |
Symposium 4 (NUSANTARA)
Evolving Strategies in Nutritional Management of CKD |
| 12.30-12.50 | SGLT2 inhibitor Role in Optimizing Kidney Outcome in CKD Patient | Optimal Nutritional Care in CKD Patients |
| 12.50-13.10 | Novel Potassium Binder in Managing Hyperkalemia to Maintain RAASi Cardiorenal Protection | Incremental Dialysis and The Role of Low Protein Diet with Ketoanalog to Preserve Residual Kidney Function |
| 13.10-13.30 | Discussion Session | |
| 12.30-14.30 | LUNCH | |
| 14.30-15.30 |
Symposium 5 (MANGUPURA)
A-Z Management of CKD: From Delay the Progression until Supportive Therapy |
Symposium 6 (NUSANTARA)
Glomerulonephritis, the New Insight |
| 14.30-14.50 | Early detection and delay progressiveness of CKD | Sign and Simptom, Early Detection Suspected Patient with GN; Model of Care |
| 14.50-15.10 | Conservative Kidney Management in Elderly with ESRD, When and how to start? | Clinicopathological Association dan Clinical Spectrum of GN |
| 15.10-15.30 | Discussion Session | |
| 15.30-16.30 |
Symposium 7 (MANGUPURA)
Blood Pressure Management on Chronic Kidney Disease |
YOUNG INVESTIGATION AWARD
(NUSANTARA) Competition Judges |
| 15.30-15.50 | Blood Pressure Management and Slowing the Progression of Chronic Kidney Disease | |
| 15.50-16.10 | Blood Pressure Treatment in Hemodialysis Patients | |
| 16.10-16.30 | Discussion Session | |
| 16.30 | CLOSING OF THE FIRST DAY OF THE SYMPOSIUM | |
| 16.30 | COFFEE BREAK | |
| 18.00-20.00 |
PERNEFRI (InaSN) NIGHT
(MANGUPURA) |
|
| WITA | Saturday, October 12th 2024 | |
|---|---|---|
| Time | SYMPOSIUM PARAREL 1 | SYMPOSIUM PARAREL 2 |
| 08.00-08.30 |
Plenary 3
Novel Biomarkers for Early Detection of Kidney Injury |
|
| 08.30-09.00 |
Plenary 4 (MANGUPURA)
Trajectory the Future Management of CKD Targeting SGLT2 Receptor |
|
| 09.00-09.30 | COFFEE BREAK | |
| ROOM | Parallel A (MANGUPURA) | Parallel B (NUSANTARA) |
| 09.30-10.30 |
Symposium 8 (MANGUPURA)
Empaglifozin; A Breakthrough in Comprehensive and Holistic Management of Patients with CKD |
Symposium 9 (NUSANTARA)
Managing Anemia in Pre-dialysis Patients |
| 09.30-09.50 | Clinical Evidence from EMPA-KIDNEY | An Overview of the Concept of Anemia in Patients with Predialysis and Effective Management Strategies |
| 09.50- 10.10 | Long Term Cost-Effectiveness of Empaglifozin in CKD, Learning from the Data of EMPA-KIDNEY Trial | Anemia Management in Predialytic Patients and the Utilization of Long-Acting Erythropoietin. |
| 10.10-10.30 | Discussion Session | |
| 10.30-11.30 |
Symposium 10 (MANGUPURA)
Hemodiafiltration |
Symposium 11 (NUSANTARA)
A New Hope for ADPKD Patients |
| 10.30-10.50 | Practical Consideration on High Volume HDF | The Importance of Early Diagnosis and Management of Rapidly Progressing ADPKD with Tolvaptan |
| 10.50-11.10 | The CONVINCE Study compares high volume HDF with standard high-flux HD | Practical Implementation of ADPKD Management: What Can We Learn from Korea |
| 11.10-11.30 | Discussion Session | |
| 11.30-12.30 |
Symposium 12 (MANGUPURA) Hemoadsorption: Past, Present and Future |
|
| 30’ | Discussion Session | |
| 12.30-12.45 | Report and Optimalization IRR Data for Research and Publication | |
| 15’ | Discussion Session | |
| 13.00-14.00 | LUNCH | |
| 14.00-15.00 |
Symposium 14 (MANGUPURA)
Mineral and Bone Disorders in Chronic Kidney Disease |
Symposium 15 (NUSANTARA)
Is GLP-1 RA Semaglutide Once-Weekly the New Kid on the Block? |
| 14.00-14.20 | The New Perspective in Pathogenesis and Diagnosis of CKD-MBD (Focus on Bone-Vascular Axis and CV Outcome) | Multifactorical Approach in Managing People with Diabetic Kidney Disease |
| 14.20-14.40 | Update Management According to Various Biochemical Abnormalities in CKD-MBD | Subtopic: New Data from FLOW Trial: What Can We Learn About Semaglutide for People with Diabetic Kidney Disease? |
| 14.40-15.00 | Discussion Session | |
| 15.00-16.00 |
Symposium 16 (MANGUPURA)
Core Concept and Update on Acute Kidney Injury |
Symposium 17 (NUSANTARA)
Nefrology Oncology Best Practice |
| 15.00-15.20 | Current Perspective Management AKI in Pediatric and Adolescent | Clinical Aspects in Nephrology Oncology Patients: How We Manage |
| 15.20-15.40 | Challenge in Management of AKI in Adult Patient | How to Use and Monitor Anti-Cancer Drugs in Patients with Kidney Disease |
| 15.40-16.00 | Discussion Session | |
| 16.00-16.30 |
CLOSING CEREMONY (MANGUPURA) |
|
